EBF1 and acute lymphoblastic leukemia: While Ph-pos ALL results from a t(9;22) translocation creating a BCR-ABL1 fusion; this subset of Ph-like ALL cases involve the fusion of another gene expressed during lymphocyte differentiation such as EBF1, SSBP2, ETV6, NUP214 with a gene encoding a tyrosine kinase or a receptor tyrosine kinase such as PDGFRB, CSF1R, ABL1 or ABL2. ALL patients with these ABL-class fusions are generally sensitive to tyrosine kinase inhibitors (TKI) including dasatinib in vitro [3] and adjuvant TKIs in patients [4, 5].